Mamoru Narukawa

986 total citations
112 papers, 644 citations indexed

About

Mamoru Narukawa is a scholar working on Economics and Econometrics, Pharmacology and Statistics and Probability. According to data from OpenAlex, Mamoru Narukawa has authored 112 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Economics and Econometrics, 28 papers in Pharmacology and 28 papers in Statistics and Probability. Recurrent topics in Mamoru Narukawa's work include Health Systems, Economic Evaluations, Quality of Life (42 papers), Pharmaceutical Economics and Policy (33 papers) and Statistical Methods in Clinical Trials (28 papers). Mamoru Narukawa is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (42 papers), Pharmaceutical Economics and Policy (33 papers) and Statistical Methods in Clinical Trials (28 papers). Mamoru Narukawa collaborates with scholars based in Japan, United States and Germany. Mamoru Narukawa's co-authors include Masayuki Kaneko, Manabu Murakami, Masahiro Takeuchi, Kenji Yamashita, Tatsuya Watanabe, Masahiko Sato, Taro Shuin, Keiji Inoue, Masafumi Oyama and Munehisa Ueno and has published in prestigious journals such as PLoS ONE, Clinical Pharmacology & Therapeutics and Drug Discovery Today.

In The Last Decade

Mamoru Narukawa

98 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mamoru Narukawa Japan 12 194 102 82 70 69 112 644
Jacqueline Corrigan‐Curay United States 9 148 0.8× 135 1.3× 23 0.3× 119 1.7× 44 0.6× 13 616
Frédéric Balusson France 14 56 0.3× 43 0.4× 33 0.4× 58 0.8× 151 2.2× 38 469
Christian Leporini Italy 14 41 0.2× 186 1.8× 64 0.8× 116 1.7× 54 0.8× 24 715
Craig E. Grossman United States 11 43 0.2× 203 2.0× 43 0.5× 67 1.0× 102 1.5× 24 784
H. Amy Xia United States 15 175 0.9× 44 0.4× 25 0.3× 19 0.3× 9 0.1× 27 776
Prasun Subedi United States 10 142 0.7× 60 0.6× 31 0.4× 80 1.1× 97 1.4× 22 434
Michele Fusaroli Italy 13 26 0.1× 48 0.5× 30 0.4× 184 2.6× 155 2.2× 45 562
Lucia Gozzo Italy 15 127 0.7× 91 0.9× 29 0.4× 74 1.1× 15 0.2× 39 664
Paolo Baldo Italy 14 47 0.2× 134 1.3× 47 0.6× 238 3.4× 181 2.6× 32 819
Efrosini Setakis United Kingdom 16 39 0.2× 121 1.2× 51 0.6× 44 0.6× 44 0.6× 29 1.0k

Countries citing papers authored by Mamoru Narukawa

Since Specialization
Citations

This map shows the geographic impact of Mamoru Narukawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mamoru Narukawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mamoru Narukawa more than expected).

Fields of papers citing papers by Mamoru Narukawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mamoru Narukawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mamoru Narukawa. The network helps show where Mamoru Narukawa may publish in the future.

Co-authorship network of co-authors of Mamoru Narukawa

This figure shows the co-authorship network connecting the top 25 collaborators of Mamoru Narukawa. A scholar is included among the top collaborators of Mamoru Narukawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mamoru Narukawa. Mamoru Narukawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saito, Kaku & Mamoru Narukawa. (2025). Bridging Gaps in Oncology: Comparative Analysis of Development and Approval Pathways for Anticancer Drugs and Companion Diagnostic in the United States and Japan. Clinical and Translational Science. 18(2). e70162–e70162. 1 indexed citations
2.
Narukawa, Mamoru, et al.. (2025). Comparison of Oncology Drug Lag in Japan and South Korea Based on the Interval between the U.S. Approval and the Local Approval. Biological and Pharmaceutical Bulletin. 48(1). 11–16. 2 indexed citations
3.
Narukawa, Mamoru, et al.. (2023). Oncology drug lag in Japan: has it improved over the last decade?. International Journal of Clinical Oncology. 28(11). 1451–1460. 9 indexed citations
4.
Ito, Akira & Mamoru Narukawa. (2023). Impact of the US Accelerated Approval for New Anticancer Drugs on Time to Verification of Benefit and Regulatory Approval in the EU and Japan. Therapeutic Innovation & Regulatory Science. 58(1). 136–142. 1 indexed citations
5.
6.
Narukawa, Mamoru, et al.. (2022). Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Control. 29. 2905558742–2905558742. 3 indexed citations
7.
Narukawa, Mamoru, et al.. (2022). Impact of the Economic Status of the Patient’s Country of Residence on the Outcome of Oncology Clinical Trials. The Oncologist. 27(3). e244–e250. 2 indexed citations
8.
Narukawa, Mamoru, et al.. (2022). Emergence of New Drugs for Intractable Diseases is Associated with an Increase in the Number of Patients Diagnosed Thereafter with Those Intractable Diseases. Therapeutic Innovation & Regulatory Science. 57(1). 70–78. 2 indexed citations
9.
Kaneko, Masayuki, et al.. (2021). Factors Influencing Regulatory Decision-Making in Signal Management: Analysis Based on the Signals Identified from the FAERS. Therapeutic Innovation & Regulatory Science. 55(4). 685–695. 1 indexed citations
10.
Narukawa, Mamoru, et al.. (2021). Increased availability of drugs is correlated with the number of patients diagnosed thereafter: Data analysis of 45 intractable diseases. Journal of Clinical Pharmacy and Therapeutics. 46(5). 1319–1325. 2 indexed citations
11.
12.
Kaneko, Masayuki, et al.. (2018). <b>Comparative Analysis of Safety Concerns and Pharmacovigilance Activities in Japan and Europe </b>. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 49(1). 23–34. 2 indexed citations
13.
Kaneko, Masayuki, et al.. (2018). Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA. Pharmacoepidemiology and Drug Safety. 27(12). 1402–1408. 39 indexed citations
14.
Kawai, Akira, Toshio Goto, Tatsuhiro Shibata, et al.. (2018). Current state of therapeutic development for rare cancers in Japan, and proposals for improvement. Cancer Science. 109(5). 1731–1737. 9 indexed citations
15.
Narukawa, Mamoru, et al.. (2017). <b>Investigation of the Development History and Status of Risk Identification for Drugs that Received First Global Approved in Japan </b>. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 48(1). 9–14. 2 indexed citations
16.
Watanabe, Tatsuya & Mamoru Narukawa. (2016). <b>Questionnaire Survey of Hospital Pharmacists on the Use of Information in Package Inserts Focusing on Safety Information</b>. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 47(1). 3–10.
17.
Kaneko, Masayuki, et al.. (2015). <b>The Current Status of All-Case Surveillance Study in Japan and Factors Influencing the Judgment of Its Necessity</b>. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 46(4). 185–189. 5 indexed citations
18.
Watanabe, Tatsuya, et al.. (2012). The Current Status of Post-Marketing Surveillance in Japan and Future Challenges. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 43(5). 345–351. 5 indexed citations
19.
Narukawa, Mamoru, et al.. (2008). . Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 39(6). 261–268.
20.
Narukawa, Mamoru. (2000). New Policy on the Utilization of Foreign Clinical Data and Our Future Task.. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 31(2). 229–236. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqueline Corrigan‐Curay Breakdown of academic impact, for papers by Frédéric Balusson Breakdown of academic impact, for papers by Christian Leporini Breakdown of academic impact, for papers by Craig E. Grossman Breakdown of academic impact, for papers by H. Amy Xia Breakdown of academic impact, for papers by Prasun Subedi Breakdown of academic impact, for papers by Michele Fusaroli Breakdown of academic impact, for papers by Lucia Gozzo Breakdown of academic impact, for papers by Paolo Baldo Breakdown of academic impact, for papers by Efrosini Setakis
Rankless by CCL
2026